Novavax (NVAX) Capital Expenditures Growth (1y) (2011 - 2026)
Powered by 
Analysis
Novavax (NVAX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 22,433.30% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -73.62% |
| 10 | Novavax | 1.67 Bn | 951.85 Mn | 42.45 Mn | 11.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.57% |
| Mar 31, 2026 | -20.38% |
| Dec 31, 2025 | 7.45% |
| Sep 30, 2025 | -0.73% |
| Jun 30, 2025 | -81.67% |
| Mar 31, 2025 | -76.81% |
| Dec 31, 2024 | -78.14% |
| Sep 30, 2024 | -92.44% |
| Jun 30, 2024 | -58.77% |
| Mar 31, 2024 | -65.26% |
| Dec 31, 2023 | -61.61% |
| Sep 30, 2023 | -26.28% |
| Jun 30, 2023 | -71.63% |
| Mar 31, 2023 | 17.68% |
| Dec 31, 2022 | 72.08% |
| Sep 30, 2022 | 102.06% |
| Jun 30, 2022 | 62.21% |
| Mar 31, 2022 | 22.10% |
| Dec 31, 2021 | -68.04% |
| Sep 30, 2021 | 39.70% |